Preferred supplier contracts in post-patent prescription drug markets-Reference-Cited by-同舟云学术

Preferred supplier contracts in post-patent prescription drug markets

Published:2016-02-22 Issue:3 Volume:20 Page:419-432
ISSN:1386-9620
Container-title:Health Care Management Science
language:en
Short-container-title:Health Care Manag Sci

Author:

Blankart Carl Rudolf,Stargardt Tom

Publisher

Springer Science and Business Media LLC

Subject

General Health Professions,Medicine (miscellaneous)

Link

http://link.springer.com/article/10.1007/s10729-016-9362-6/fulltext.html

Reference46 articles.

1. IMS Health (2011) The global use of medicined: Outlook Through 2015. IMS Institute for Healthcare Informatics

2. IMS Health (2011) The use of medicines in the United States: review of 2010. IMS Institute for Healthcare Informatics, Parsippany

3. Kanavos P, Seeley E, Vandoros S (2010) Tender systems for outpatient pharmaceuticals in the European Union: Evidence from the Netherlands, Germany and Belgium. Enterprise and Industry, European Commission

4. Fischer M, Albers S (2010) Patient- or physician-oriented marketing: what drives primary demand for prescription drugs? J Mark Res 47(1):103–121. doi: 10.1509/jmkr.47.1.103

5. Hellerstein JK (1998) The importance of the physician in the generic versus trade-name prescription decision. RAND J Econ 29(1):108–136

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pricing, Procurement and Reimbursement Policies for Incentivizing Market Entry of Novel Antibiotics and Diagnostics: Learnings from 10 Countries Globally;Applied Health Economics and Health Policy;2024-06-05

2. The impact of pharmaceutical tendering on prices and market concentration in South Africa over a 14-year period;Social Science & Medicine;2019-01

3. Shaping Pharmaceutical Tenders for Effectiveness and Sustainability in Countries with Expanding Healthcare Coverage;Applied Health Economics and Health Policy;2018-07-10

4. The impact of physician-level drug budgets on prescribing behavior;The European Journal of Health Economics;2017-02-13

5. Cost-Sharing and Drug Pricing Strategies: Introducing Tiered Co-Payments in Reference Price Markets;SSRN Electronic Journal;2016